Construction of Pharma in Ireland and the EU

  • March 7, 2024

Construction of Pharma in Ireland and the EU

Ireland’s pharmaceutical sector has solidified its position as a cornerstone of the European Union’s healthcare and economic landscapes.

As the largest net exporter of pharmaceuticals in the EU, representing over half of the country’s exports, Ireland is a pivotal gateway for North American companies into Europe. Home to 50 FDA-approved pharma and biopharma plants, Ireland’s strategic importance cannot be overstated.

This burgeoning role as a hub for pharmaceutical construction and manufacturing showcases Ireland’s dynamic capability to attract significant global investments, driving forward innovations in healthcare and economic growth within the EU.

Investment Climate in Ireland for Pharma Construction

The investment climate in Ireland is increasingly favourable for pharmaceutical construction, evidenced by Dexcom’s commitment to establish its first European manufacturing site with a €300 million investment.

This move is part of a broader construction boom in the sector, highlighting Ireland’s attractiveness for major pharmaceutical investments. With its conducive business environment, strategic location, and robust support infrastructure, Ireland is cementing its status as a premier destination for the pharma industry’s expansion and construction projects, promising substantial economic growth and job creation.

3 Factors Attracting Pharmaceutical Companies to Ireland

Ireland’s allure for pharmaceutical companies is not by chance but the result of a combination of strategic advantages that the country offers. These factors not only facilitate the construction of new facilities but also ensure the long-term success of these ventures.

  1. Tax Benefits: Ireland offers one of the most favourable corporate tax environments in the EU, making it a financially attractive location for pharma companies.
  2. Skilled Workforce: The country’s education system produces a steady stream of highly skilled graduates, particularly in science, technology, engineering, and mathematics (STEM), essential for the pharma industry.
  3. Pro-Business Environment: Ireland’s government policies and regulatory frameworks support business growth and innovation, creating a welcoming atmosphere for pharma construction and expansion.

Impact of EU Strategies on Pharma Construction in Ireland

Pharma in Europe

The EU’s Pharmaceutical Strategy for Europe significantly impacts the construction trends in Ireland’s pharma sector.

This strategy aims to ensure access to affordable medicines and support the industry’s competitiveness and innovation. Its focus on enhancing the pharmaceutical production capacity within the EU aligns with Ireland’s strengths, encouraging further construction of state-of-the-art pharmaceutical manufacturing and R&D facilities.

This alignment ensures Ireland remains an attractive destination for pharma companies looking to expand in line with EU health and regulatory goals.

Case Studies: Success Stories of Pharma Construction

Ireland’s pharmaceutical sector showcases several success stories, such as:

  • Pfizer’s Facility Expansion: Pfizer‘s construction of a cutting-edge manufacturing facility in Ireland, requiring an investment of €1.2bn, showcases the country’s capability to host large-scale, technologically advanced pharma projects, benefiting from the skilled local workforce and supportive government policies.
  • Regeneron’s Limerick Site: Regeneron‘s significant investment in expanding its biopharmaceutical operations in Limerick is another testament to Ireland’s attractiveness. This project highlights the effective collaboration between multinational corporations, the Irish government, and educational institutions, leading to job creation and economic growth.

Challenges and Opportunities in Pharma Construction

The construction of pharmaceutical facilities in Ireland presents a unique set of challenges and opportunities, impacting both the local economy and the workforce in significant ways.

Regulatory and Environmental Compliance: Navigating Ireland’s stringent regulatory landscape and environmental standards can be complex, requiring substantial planning and expertise.

Opportunity: Meeting these high standards can enhance a company’s reputation and commitment to sustainability.

High Technological Demands: The need for cutting-edge technology in pharma construction requires significant investment and expertise.

Opportunity: This drives innovation and the development of a highly skilled tech-savvy workforce.

Supply Chain Logistics: Ensuring the timely and efficient delivery of materials can be challenging due to global supply chain volatility.

Opportunity: Encourages the development of robust local supply chains and partnerships.

Workforce Development: The specialised nature of pharmaceutical manufacturing necessitates a highly educated and skilled workforce.

Opportunity: Stimulates investment in education and training programs, boosting employment and skill levels within the local community.

Future Outlook for Pharma Construction in Ireland and the EU

As Ireland and the EU navigate the future landscape of pharmaceutical construction, several factors are poised to shape the trajectory of this vital industry.

  • Increasing focus on environmentally friendly construction practices aligns with the EU’s sustainability goals.
  • The sector will likely see greater investment in cutting-edge technologies, improving manufacturing processes and efficiency.
  • Ongoing adaptations to EU regulations will necessitate advanced compliance measures in facility design and operation.
  • Ireland’s unique position as an English-speaking EU member will continue to attract significant global investments.
  • The industry must remain adaptable to rapidly construct specialised facilities in response to emerging health crises.
  • Enhanced focus on education and training initiatives to prepare a skilled workforce for future industry needs.


Ireland’s strategic advantages, from its pro-business environment and skilled workforce to favourable tax rates, position it as an ideal location for pharmaceutical construction within the EU.

The synergy between government policies, educational institutions, and global pharmaceutical companies fosters a conducive environment for innovation and growth.

As Ireland continues to adapt to global health trends and EU regulations, its role in the pharmaceutical sector is set to expand, offering ongoing benefits to the industry, including job creation, economic growth, and maintaining its status as a key player in global healthcare.

Connecting candidates with the right employers first time, every time.